



Join us for an educational program during the Midwest Burn Conference 2023

The ABCs of NexoBrid® (anacaulase-bcdb)

Advancing Burn Care

Please see **IMPORTANT SAFETY INFORMATION** below and [Full Prescribing Information](#).

Monday October 9th
7:00pm–9:00pm CT

Canopy by Hilton Minneapolis Mill District
708 S 3rd St, Minneapolis, MN 55415

P R E S E N T E D B Y :



Lucy Wibbenmeyer, MD, FACS

Director of Burn Center
Clinical Professor
Clara L. Smith Professor in Burn Treatment
Acute Care Surgery
University of Iowa Hospitals and Clinics

Topics presented will include:

- Presentation of NexoBrid® (anacaulase-bcdb) product background, clinical trial data, and application
- Case presentations and product use considerations

REGISTER NOW

This program is sponsored by Vericel Corporation and is not eligible for CE credits. This speaker is a paid consultant of Vericel Corporation.

INDICATION

NEXOBRID® (anacaulase-bcdb) is indicated for eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

Limitations of Use

The safety and effectiveness of NEXOBRID have not been established for treatment of:

- Chemical or electrical burns
- Burns on the face, perineum, or genitalia
- Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
- Circumferential burns
- Burns in patients with significant cardiopulmonary disease, including inhalation injury

NEXOBRID is not recommended for wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

NEXOBRID is contraindicated in patients with: known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or to any other components; known hypersensitivity to papayas or papain because of the risk of cross-sensitivity.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb.

Pain Management

Manage pain as appropriate for an extensive dressing change of burn wounds. At least 15 minutes prior to NEXOBRID-related procedures ensure adequate pain control measures are in place.

Proteolytic Injury to Non-Target Tissues

NEXOBRID is not recommended for treatment of burn wounds where medical devices or vital structures could become exposed during eschar removal.

Coagulopathy

Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution in patients on anticoagulant therapy or other drugs affecting coagulation, and in patients with low platelet counts and increased risk of bleeding from other causes. Monitor patients for possible signs of coagulation abnormalities and signs of bleeding.

ADVERSE REACTIONS

The most common adverse reactions (>10%) were pruritus and pyrexia.

USE IN SPECIAL POPULATIONS

Geriatric Use

Clinical studies of NEXOBRID did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

To report negative side effects contact Vericel Corporation at 888-454-BURN (888-454-2876) or FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

Please see [Full Prescribing Information](#).

Restrictions for US HCPs: In compliance with the PhRMA Code on Interactions with Healthcare Professionals, guests and/or spouses will not be permitted to attend. Please note that Vericel is subject to several laws that restrict the provision of food and beverage in connection with an event. In particular, some state and local jurisdictions, such as Vermont, Louisiana and Minnesota, prohibit or limit companies like Vericel from providing food and beverage to HCPs. Please disclose if you are licensed in a state or work in a jurisdiction or facility that limits or prohibits HCPs from partaking in a meal or refreshments. Any HCPs with meal/refreshment prohibitions are required to opt-out as noted on the sign-in form. Vericel is also subject to other federal disclosure laws. Vericel will report the name and value received for all HCPs who receive a meal as required by law. So that we may comply with federal and state disclosure laws, Vericel Corporation requires all practitioners in attendance to sign in. On the sign-in sheet, you have the option to indicate your non-participation in the meal offered in connection with this program. If selected, Vericel Corporation will not report a transfer of value to you.

Restrictions for International HCPs: HCPs from outside of the US may not attend this promotional program about US FDA-approved products.

www.NexoBrid-US.com

VERICEL Burn Care

Committed to advancing therapies